Results 61 to 70 of about 19,009 (196)
Developing novel antiviral drugs has always been a significant forefront in biological medicine research. Antiviral drugs can be extracted, purified, and synthesized from various biological sources and by different methods.
Shaotang Ye +7 more
doaj +1 more source
Cell‐Based Micro/Nanorobots: From Living Carriers to Living Therapeutic Specialists
Cell‐based micro/nanorobots integrate evolutionarily acquired biological intelligence with engineered capabilities, offering new opportunities for precision medicine in vivo. However, the complex physiological environments of different organs pose significant challenges to their clinical translation.
Junfeng Wu +12 more
wiley +1 more source
Decitabine promotes efficient erythroid differentiation from transduced CD34+ cells.
(a) To evaluate decitabine effects on erythroid differentiation and transduction efficiency, we transduced human CD34+ cells with a GFP-expressing HIV-1 vector following 48-hour prestimulation with 0.5 µM decitabine.
Yogen Saunthararajah (320626) +4 more
core +1 more source
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick +7 more
wiley +1 more source
A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis +3 more
wiley +1 more source
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
Hypermethylation of tumor suppressor genes is a hallmark of leukemia. The hypomethylating agent decitabine covalently binds, and degrades DNA (cytosine‐5)‐methyltransferase 1 (DNMT1).
Luisa Brock +10 more
doaj +1 more source
New lipid nanocapsules for decitabine encapsulation [PDF]
Introduction:Currently decitabine, an antimetabolite agent is approved for acute myeloid leukemia in old patients and is administered via intra-venous (IV) route.
Roger, Emilie +3 more
core +2 more sources
Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. [PDF]
Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome (MDS). However, the optimal regimen for decitabine treatment is not well established.
Xiao Li +12 more
doaj +1 more source
Qing Ya Wang,* Yuan Li,* Ze Yin Liang, Yue Yin, Wei Liu, Qian Wang, Yu Jun Dong, Yu Hua Sun, Wei Lin Xu, Han Yun Ren Department of Hematology, Peking University First Hospital, Peking University, Beijing, People’s Republic of China*These authors ...
Wang QY +9 more
doaj
Summary Lack of response or delayed response to therapy are major challenges in the use of DNA‐hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single‐centre studies.
Julia Stomper +27 more
wiley +1 more source

